Drug intelligence / Profile preview

HMR-322017

Development stage: Phase 1
Lead developer: Neurocrine Biosciences

Overview

HMR-322017 is an early-stage investigational drug candidate developed by Neurocrine Biosciences. It was evaluated in a Phase 1 clinical trial (HMR code 22-017) in healthy human volunteers in the United Kingdom, which was completed in late 2024. Due to commercial sensitivity, the sponsor deferred the public disclosure of the trial protocol, drug identity, mechanism of action, and specific therapeutic targets. Consequently, no detailed pharmacological or chemical information is currently available in public registries.

Beyond the preview

Go deeper on HMR-322017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMR-322017.